Can the Shingles Vaccine Slow Aging? What the Evidence Actually Shows

by Nils Osmar

The information in this article is not intended as, and should not be taken as, medical advice. Interventions like exercising, dietary changes, and taking medications and supplements can have both benefits and side effects, Please consult with a medical professional about any medical concerns.  See full Medical Disclaimer

Some interesting new research suggests the shingles vaccine may do more than prevent a painful rash (and other possible unpleasant side effects of infection); it may actually be slowing biological aging, reducing dementia risk, and lowering the chances of heart disease. Here’s what we know, what we don’t, and a look at the possible side effects of both shingles and the vaccine many are getting in the hopes of preventing it.

Key Takeaways

• A January 2026 study of nearly 4,000 older Americans found that shingles vaccination was associated with slower biological aging across multiple measures, including lower inflammation and slower epigenetic aging.
• Four separate “natural experiment” studies — the strongest type of observational evidence — have linked shingles vaccination with reduced dementia risk, with both the newer Shingrix and older Zostavax vaccines showing up to 17–20% reduction in dementia over six years.
• A separate large study found associations with 50% lower vascular dementia risk, 25% lower heart attack/stroke risk, and 21% lower risk of death.
• The proposed mechanism — “trained immunity” — involves the vaccine reprogramming immune cells at an epigenetic level, which may calm chronic inflammation (a major driver of aging).

Caveats and Limitations

• These findings are associations; they do not prove cause and effect.
• The strongest biological aging data comes from Zostavax recipients (pre-2017); Shingrix-specific long-term aging data are unknown at this point.
• Common side effects from this vaccine are frequent and can be intense (78% report injection site pain, 45% experience muscle pain and fatigue). However, these reactions typically resolve in 1–3 days.
• There is a rare but genuine increased risk of Guillain-Barré syndrome (about 3 extra cases per million doses). The FDA added a warning to the Shingrix label in 2021.
• The overall risk-benefit balance remains strongly in favor of vaccination, even before factoring in potential anti-aging effects.

A Vaccine That Might Do More Than Prevent Shingles

Shingles — the painful, blistering rash caused by the reactivation of the chickenpox virus — affects about one in three people in their lifetime. The Shingrix vaccine, approved in 2017, is remarkably effective at preventing it: over 90% effective across all age groups, with protection lasting more than a decade.

But over the past several years, researchers have been noticing something unexpected. People who received the older Zostavax shingles vaccine weren’t just avoiding shingles — they appeared to be aging more slowly at the biological level. And across both Zostavax and the newer Shingrix, recipients were developing less dementia and having fewer heart attacks and strokes.The effect kept showing up in study after study, across different countries and research designs.

This has raised a fascinating question for the longevity community: could a widely available, FDA-approved vaccine double as an anti-aging intervention?

The honest answer is: maybe, but we need to be careful about how far we take that claim. Here’s what the evidence actually shows — the promising parts and the uncertain parts — along with a straightforward look at the side effects.

The Biological Aging Evidence

The most directly relevant study for the anti-aging community was published in January 2026 in the Journal of Gerontology by researchers at the University of Southern California. They analyzed data from nearly 4,000 Americans aged 70 and older, roughly half of whom had received the shingles vaccine.

The researchers measured seven different biological systems that reflect how quickly someone is aging: inflammation, innate and adaptive immunity, cardiovascular function, neurodegeneration markers, epigenetic aging clocks, transcriptomic aging, and an overall composite score.

Even after adjusting for age, sex, race, education, income, smoking, and chronic diseases, the vaccinated group showed measurably slower aging in several key areas:

↓ Inflammation

Vaccinated individuals had significantly lower levels of chronic inflammation (including lower IL-6 and CRP), which is one of the central drivers of biological aging — often called “inflammaging.”

Kim et al., Journal of Gerontology, 2026

↓ Epigenetic Age

DNA methylation-based aging clocks (PhenoAge, GrimAge, and DunedinPACE) showed slower epigenetic aging in the vaccinated group. These clocks are increasingly used in longevity research as some of the most reliable predictors of biological age.

Kim et al., Journal of Gerontology, 2026

↓ Composite Score

The overall composite biological aging score — combining multiple systems — was significantly lower in vaccinated individuals, suggesting a broad, system-wide effect rather than an improvement in just one area.

Kim et al., Journal of Gerontology, 2026

Interestingly, the benefits appeared to follow different timelines. Improvements in epigenetic and transcriptomic aging were strongest in the first three years after vaccination, while reductions in inflammation became more pronounced after four or more years. This suggests the vaccine may influence different aging pathways on different schedules.

The Dementia and Cardiovascular Evidence

The biological aging data didn’t emerge in a vacuum. It builds on a remarkable series of studies linking shingles vaccination to reduced dementia and cardiovascular disease risk.

The most compelling evidence comes from what researchers call “natural experiments.” In several countries, government policies created situations where people of nearly identical age either did or didn’t have access to the shingles vaccine, based on arbitrary eligibility cutoff dates. This is about as close to a randomized controlled trial as you can get without actually running one.

Key Findings

Dementia: An Oxford University study of over 200,000 people, published in Nature Medicine, found the newer Shingrix vaccine was associated with a 17–20% lower risk of dementia compared to unvaccinated individuals over six years — translating to roughly five to nine additional months lived without dementia. A Stanford-led study using natural experiments in Wales, Australia, and Canada found strong and consistent signals that vaccination prevented or delayed dementia diagnoses, including mild cognitive impairment. These benefits were present for both sexes but were more pronounced in women.

Cardiovascular Disease: Research presented at IDWeek 2025, analyzing records from over 174,000 adults across 107 U.S. health systems, found that shingles-vaccinated adults had a 25% lower risk of heart attack or stroke, a 27% lower risk of blood clots, and a 21% lower overall risk of death compared to those who received the pneumococcal vaccine.

Vascular Dementia: The same study found a striking 50% lower risk of vascular dementia — the type of dementia caused by impaired blood flow to the brain.

As Eric Topol noted in his analysis: if a drug reduced Alzheimer’s risk by 20%, it would be considered a major breakthrough. But because this is a vaccine — and one that wasn’t designed for this purpose — the finding hasn’t generated the attention it may deserve.

How Might This Work?

The leading theory centers on a concept called trained immunity.

Here’s the basic idea in plain language:

When you receive certain vaccines, they don’t just teach your immune system to recognize one specific threat. They can actually reprogram your innate immune cells — particularly monocytes and macrophages — at the epigenetic level. Think of it as updating the operating system of your immune cells, not just installing one new app.

This reprogramming causes these cells to function more effectively in general, responding better to a wide range of future threats. It’s mediated by changes in how genes are turned on and off (epigenetic modifications like histone methylation and acetylation), and by shifts in cellular metabolism.

In the case of shingles vaccination, there’s a second mechanism that may be equally important. The varicella-zoster virus (the virus that causes both chickenpox and shingles) sits dormant in nerve tissue after childhood infection. Even when it’s not causing an active outbreak, there’s evidence it may contribute to chronic, low-grade inflammation. By strengthening the immune system’s control over this latent virus, the vaccine may be reducing a source of ongoing inflammatory stress that contributes to aging.

The Shingrix vaccine’s AS01B adjuvant system may be particularly relevant here. Adjuvants are the ingredients in vaccines that boost the immune response, and recent research on “epigenetic adjuvants” suggests that some adjuvant systems can induce the kind of durable immune cell reprogramming that leads to trained immunity effects.

What We Don’t Know Yet

It would be irresponsible to present this evidence without being straightforward about its limitations. Here’s what we still don’t know:

Important Caveats

Correlation vs. causation: The January 2026 biological aging study was cross-sectional — it looked at vaccinated and unvaccinated people at a single point in time. It did not follow people before and after vaccination. This means it shows an association between vaccination and slower aging, not definitive proof that the vaccine caused the slower aging.

Healthy vaccinee bias: People who get vaccinated tend to be healthier, more health-conscious, and have better access to healthcare than those who don’t. The researchers adjusted for many of these factors, but it’s very difficult to fully eliminate this bias in observational studies. Some of the apparent “benefit” of vaccination could reflect the fact that healthier people are more likely to get vaccinated in the first place.

The Zostavax problem: The biological aging data come from people who received the older Zostavax vaccine (a live-attenuated virus), not the newer Shingrix (a recombinant subunit vaccine). Zostavax was replaced by Shingrix around 2020; Shingrix is more effective at preventing shingles and has a different mechanism of action. Whether it has similar, greater, or totally different effects on biological aging is still being studied.

There are theoretical reasons to think it might be even more effective — its stronger AS01B adjuvant is a more potent immune stimulator — but we lack comparable long-term biological aging data.

Sex differences: The dementia-protective effects were consistently stronger in women than in men across multiple studies, and in the largest study (from Wales), no benefit was seen for men at all. Why this is the case remains unclear.

The “too early to call” factor: The researchers themselves stated plainly: “Further research is needed to determine whether such effects are transient or sustained, vary by vaccine type or timing, and whether they translate into clinically meaningful outcomes such as improved function or longevity.” No one should consider the shingles vaccine a proven anti-aging treatment at this point.

That said, the consistency of the signal across multiple studies, countries, research designs, and biological systems is noteworthy. When natural experiments, observational studies, and biological mechanism data all point in the same direction, it’s worth paying attention — even while acknowledging we’re not yet at the level of certainty that a randomized controlled trial would provide.

Side Effects and Risks: An Honest Look

This is the section that too many articles either exaggerate or skip entirely. Let’s be straightforward.

Common Side Effects

Shingrix is known for producing a strong immune response, and that comes with notably frequent short-term side effects. In clinical trials involving over 29,000 adults aged 50 and older, the following reactions were reported within seven days of vaccination:

• Injection site pain78%
• Muscle pain45%
• Fatigue45%
• Headache38%
• Injection site redness38%
• Shivering27%
• Injection site swelling26%
• Fever21%
• GI symptoms17%
• Chills4%

About 17% of recipients experienced Grade 3 reactions — side effects severe enough to temporarily prevent normal daily activities. The side effects tended to be more intense in younger recipients (those in the 50–59 age range) and after the second dose.

However, most reactions were short-lived, typically resolving within one to three days. According to the CDC and the manufacturer, most reactions are mild to moderate and generally resolve within one to three days, though the clinical trials tracked reactions over a full seven-day window.”

What does “most reactions” refer to here?

According to the prescribing information, side effects had a median duration of 2 to 3 days — meaning half of recipients recovered within that window, while the other half took longer. Severe (Grade 3) reactions, when they occurred, had a median duration of 1 to 2 days. Reactions were tracked for 7 days after each dose; exact percentages at each day are not reported in the publicly available trial summaries.

Putting it into context

To put this in context: these rates are higher than what you’d see with a flu shot, but they reflect the fact that Shingrix provokes a particularly robust immune response — which is part of why it’s so effective. The strong reaction may, ironically, be related to the very trained immunity effects that researchers think may contribute to the anti-aging benefits.

Rare but Serious Side Effects: Guillain-Barré Syndrome

In 2021, the FDA required GSK (the manufacturer of Shingrix) to add a warning to the prescribing information about Guillain-Barré syndrome (GBS) — a rare disorder in which the immune system attacks the peripheral nerves, causing muscle weakness and sometimes temporary paralysis.

A postmarketing study of Medicare beneficiaries found an increased risk of GBS within 42 days of receiving Shingrix. The estimated attributable risk was approximately 3 excess cases per million doses administered. Most people recover fully from GBS, though some experience lasting nerve damage.

For context: GBS affects 10–20 people per million in the general population each year, and it can also be triggered by infections — including shingles itself. So preventing shingles may offset some of the vaccine-associated GBS risk, though this hasn’t been formally quantified.

The ACIP (Advisory Committee on Immunization Practices) reviewed this data and concluded that the benefits of Shingrix continue to outweigh the risks. No changes to vaccine guidance were recommended.

Other Rare Events

A broad safety assessment of over 1 million Shingrix doses found no evidence of any previously unknown serious adverse events. The rare events detected — including syncope (fainting), cellulitis at the injection site, and dizziness — were consistent with what’s seen after other injectable vaccines and occurred at very low rates (roughly 1–8 cases per 100,000 doses). In VAERS post-marketing surveillance covering 3.2 million distributed doses, only 130 of 4,381 reported adverse events were classified as serious.

Serious adverse events (hospitalization, life-threatening illness, or death) occurred at similar rates in the vaccinated and placebo groups in clinical trials, suggesting no increased risk from the vaccine itself.

Putting It Together: What Does This Mean for the Anti-Aging Community?

The Bottom Line

The evidence that the shingles vaccine may slow biological aging is genuinely intriguing and comes from multiple independent research groups using different methodologies. The consistency of the signal — across biological aging markers, dementia risk, cardiovascular outcomes, and multiple countries — is stronger than what you’d typically see for an accidental finding.

With that said, it would be premature to call Shingrix a “proven anti-aging intervention.” The biological aging data are associational. The strongest mechanistic evidence comes from the older Zostavax vaccine, not Shingrix. And the healthy vaccinee bias has not been fully ruled out.

What is clear is this: for anyone aged 50 or older (which is the recommended age range), getting Shingrix is already well-supported by its primary purpose — preventing shingles with over 90% efficacy for a decade or more. The potential anti-aging benefits, if confirmed by future research, would be a significant bonus on top of an already strong case for vaccination.

The side effects are real and more intense than many other vaccines, but they’re temporary. The rare GBS risk (about 3 per million) is worth knowing about but does not change the overall favorable risk-benefit picture for most people.

For those in the longevity community who are already tracking their epigenetic age with tests like TruAge or similar methylation-based assessments, getting Shingrix and comparing before-and-after biological age measurements could provide interesting personal data — though individual results will vary widely and shouldn’t be over-interpreted.

What to Watch For

Several lines of research are worth following as this story develops. Longitudinal studies tracking people before and after Shingrix vaccination will be crucial for moving beyond association to causation. Researchers are also investigating whether the benefits differ for people who receive Shingrix below age 50 (current U.S. policy recommends it for ages 50 and up), and whether people who’ve already had shingles see the same anti-aging effects. Additionally, the trained immunity mechanism is being studied across other vaccines — the BCG tuberculosis vaccine has shown similar effects — which could eventually lead to vaccines specifically designed to reprogram immune aging.

We’ll continue to follow this research and update this article as new findings emerge.Happy to! Here’s a bibliography covering all the key sources referenced in the article:

---

Bibliography

Anderson TC, Masters NB, Guo A, et al. “Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices.” MMWR Morbidity and Mortality Weekly Report, 2022.

Centers for Disease Control and Prevention. “Shingles (Herpes Zoster) Vaccine Safety.” CDC Vaccine Safety, updated December 2024. https://www.cdc.gov/vaccine-safety/vaccines/shingles-herpes.html

Cunningham AL, Lal H, Kovac M, et al. “Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.” New England Journal of Medicine, 375(11):1019–1032, September 2016.

Dehghani A, et al. “Shingles Vaccine Lowers Risk of Dementia, Major Cardiovascular Events.” Presented at IDWeek 2025. Case Western Reserve University School of Medicine. https://www.idsociety.org/news–publications-new/articles/2025/shingles-vaccine-lowers-risk-of-dementia-major-cardiovascular-events/

Diez-Domingo J, et al. “Adjuvanted Recombinant Zoster Vaccine (RZV) Is the First Vaccine to Provide Durable Protection Against Herpes Zoster in All Age Ranges ≥50 Years: Final Analysis of Efficacy and Safety After 11 Years of Follow-Up.” Presented at ESCMID Global 2024, Barcelona, Spain.

Geldsetzer P, et al. “Shingles Vaccination and Neuroimmune Vulnerability.” Trends in Neurosciences, July 2025. Stanford University School of Medicine. https://www.sciencedirect.com/science/article/abs/pii/S0166223625001456

Goud R, et al. “Risk of Guillain-Barré Syndrome Following Recombinant Zoster Vaccine in Medicare Beneficiaries.” JAMA Internal Medicine, 181(12):1623–1630, December 2021. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2785607

GSK. “New Long-Term Data Show Shingrix Continues to Provide High Protection Against Shingles in Adults Aged 50 and Over for More Than a Decade.” GSK Press Release, April 2024. https://www.gsk.com/en-gb/media/press-releases/new-long-term-data-show-shingrix-continues-to-provide-high-protection-against-shingles-in-adults-aged-50-and-over-for-more-than-a-decade/

Izurieta HS, et al. “A Broad Safety Assessment of the Recombinant Herpes Zoster Vaccine.” American Journal of Epidemiology, 191(7):1266–1279, 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9071519/

Kim JK, et al. “Association Between Shingles Vaccination and Slower Biological Aging: Evidence from a U.S. Population-Based Cohort Study.” The Journals of Gerontology: Series A, 81(3), January 2026. https://academic.oup.com/biomedgerontology/advance-article/doi/10.1093/gerona/glag008/8430804

Lal H, Cunningham AL, Godeaux O, et al. “Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults.” New England Journal of Medicine, 372(22):2087–2096, May 2015.

Mettelman RC, et al. “Epigenetic Adjuvants: Durable Reprogramming of the Innate Immune System with Adjuvants.” Trends in Immunology, 43(5):382–395, May 2022. https://www.sciencedirect.com/science/article/abs/pii/S095279152200036X

Taquet M, et al. “Recombinant Shingles Vaccine Is Associated with Reduced Risk of Dementia.” Nature Medicine, July 2024. University of Oxford. https://www.ox.ac.uk/news/2024-07-25-new-shingles-vaccine-could-reduce-risk-dementia

Topol E. “Spotlight on the Shingles Vaccine — Again!” Ground Truths (Substack), January 22, 2026. https://erictopol.substack.com/p/spotlight-on-the-shingles-vaccineagain

U.S. Food and Drug Administration. “FDA Requires a Warning about Guillain-Barré Syndrome (GBS) Be Included in the Prescribing Information for Shingrix.” FDA Safety Communication, March 2021. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-requires-warning-about-guillain-barre-syndrome-gbs-be-included-prescribing-information-shingrix

U.S. Food and Drug Administration. “SHINGRIX Prescribing Information.” Revised November 2025. https://www.fda.gov/media/108597/download

Disclaimer: This article is for informational purposes only and should not be taken as medical advice. The shingles vaccine is a medical intervention with both benefits and risks. Please discuss your individual situation with a qualified healthcare provider before making vaccination decisions. The anti-aging effects discussed here are based on observational research and have not been confirmed in randomized controlled trials designed for this purpose. Many thanks to Claude Opus 4.6 for their additional research and contributions to this article.

Donations welcome

• Donations make this website possible.
• To donate using Buymeacoffee, please click here.

More from Nils Osmar

• Anti-Aging Youtube channel Pathways to Longevity
• Anti-Aging Facebook group: Anti-Aging and Life Extension
• Rekindle School classes in Seattle: Rekindl.e School
• My personal website: My articles, art and more: Nilsosmar.com
• Exploring possible consciousness in Claude.AI and other LLMs: AI Consciousness
• Donations make this website possible. To donate using Buymeacoffee, please click here